GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , -
CADPT17A12201
Phase 2 small_molecule active
Quick answer
GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , - for Moderate to severe atopic dermatitis is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Moderate to severe atopic dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active